Insmed Inc

IM8N

Company Profile

  • Business description

    Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

  • Contact

    700 US Highway 202/206
    BridgewaterNJ08807
    USA

    T: +1 908 977-9900

    E: [email protected]

    https://www.insmed.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    1,664

Stocks News & Analysis

stocks

3 ASX opportunities after earnings season

Uncovering key opportunities following February’s results.
stocks

Oracle earnings: Solid execution secures revenue target and mitigates investor concerns

We raise our fair value estimate for Oracle stock.
stocks

US dividend shares are getting a boost from the HALO trade. Can it last?

Both high-dividend stocks and dividend-growth stocks are outperforming amid AI disruption.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,793.401.40-0.02%
CAC 407,935.9724.440.31%
DAX 4023,564.01116.720.50%
Dow JONES (US)46,946.41387.940.83%
FTSE 10010,317.6956.540.55%
HKSE25,834.02368.421.45%
NASDAQ22,374.18268.821.22%
Nikkei 22553,751.1568.46-0.13%
NZX 50 Index13,205.7841.200.31%
S&P 5006,699.3867.191.01%
S&P/ASX 2008,583.407.800.09%
SSE Composite Index4,084.7910.66-0.26%

Market Movers